Market Overview

Seattle Genetics - No Bounce After Phase 1 Trial Put On Clinical Hold

Share:
Seattle Genetics - No Bounce After Phase 1 Trial Put On Clinical Hold

Seattle Genetics, Inc. (NASDAQ: SGEN) shares were seen trading lower by $8.68 at $53.18 in Tuesday's morning session. The catalyst for the decline is the announcement that a clinical hold has been placed on Phase 1 trial of Vadastuximab Talirine.

After a much lower open, it bottomed at $52.18 and managed a brief rally to $54.70 before resuming its move lower. It has fallen back to the $53 area, but has yet to make a new low for the session.

If the decline continues through the current low there may be additional support at its November 1 low ($51.50) as well as its October 31 low ($50.80).

Posted-In: vadastuximab talirineBiotech Technicals Intraday Update Movers Trading Ideas General

 

Related Articles (SGEN)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial
Book A Demo
Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo

ComScore: Online Spending To Grow As Much As 19% This Holiday Season

5 Things Happening Around The Internet Ad Space This Week